Abstract
Telomeres are repetitive DNA sequences located at chromosomal ends that are crucial for maintaining genomic stability. Telomere lengths are tightly regulated under physiological conditions, disruption of which results in telomere shortening that ultimately leads to telomere biology disorders, such as Dyskeratosis congenita (DC), bone marrow failure syndromes, and Idiopathic Pulmonary Fibrosis (IPF), amongst others. Progressive telomere shortening is also a well-recognized feature of aging. Although telomere shortening and anemia often go hand-in-hand in aging individuals and Myelodysplastic Syndrome (MDS) patients, the mechanistic link in between these manifestations remains poorly understood. In this regard, RIOK2 has recently emerged as a key transcriptional regulator of both blood cell development and telomerase activity. This commentary elaborates the multifaceted roles of RIOK2 in maintaining hematopoiesis and telomere length homeostasis in the context of aging, MDS and IPF, and further explores the potential of regulating RIOK2’s expression and/or function for therapeutic applications.
Keywords
RIOK2, Telomere, MDS, Aging, Telomerase, IPF